Does weekly subcutaneous semaglutide 2.4 milligrams reduce cardiovascular events in patients with obesity without diabetes?

In patients with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events more than placebo.

Randomized trial · NEJM 2023

Reference: Lincoff AM, Brown-Frandsen K, Colhoun HM. N Engl J Med. 2023; PMID:37952131.

Chapters

0:00 Intro

0:38 The trial

3:05 My take

3:42 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-generated narration. This podcast is intended for healthcare professionals and is for educational purposes only; it is not medical advice. Any views expressed are the presenter's own and do not necessarily reflect the views of any institution he works with.

Explore Hormone Insight:

Website: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en